Setting new standards in information exchange for the pharmaceutical and biotech industry
IO360 Speaker Dr. Jedd Wolchok Leads Trial that Results in FDA Approval of Opdivo Plus Yervoy in Melanoma
January 26, 2016
Earlier this week, the FDA approved the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma. The FDA based the approval on results of the phase III CheckMate-067 trial, which compared nivolumab plus ipilimumab or nivolumab alone versus ipilimumab monotherapy.
Dr. Jedd Wolchok is the principal investigator of the CheckMate-067 trial and will be delivering a talk on this combination therapy for melanoma at the 2nd Annual Immuno-Oncology 360° conference February 2-3, 2016 in NYC.
“The combination of two immuno-oncology treatments, nivolumab and ipilimumab, has been shown to provide these patients with a much needed improvement in progression-free survival and response rates,” said IO360° speaker and principal investigator in CheckMate-067, Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center in a recent statement.
The FDA expanded the approval of nivolumab plus ipilimumab to include all patients with unresectable or metastatic melanoma, regardless of BRAF V600 mutational status. Until now, the combination only had been indicated for patients with BRAF V600 wild-type disease.Nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) is the only FDA-approved combination of immune checkpoint inhibitors.
Read the full article: http://snip.ly/wRHV
To learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/